According to Research by SNS Insider, mRNA Sequencing Market Growth is Driven by Advancements in Genomics and Precision Medicine and Rising Demand for Precision Medicine.
Pune, March 19, 2025 (GLOBE NEWSWIRE) — According to SNS Insider, The mRNA Sequencing Market was valued at USD 3.6 billion in 2023 and is projected to reach USD 7.19 billion by 2032, growing at a CAGR of 8.0% during the forecast period 2024-2032. The increasing adoption of next-generation sequencing (NGS) technologies, rising demand for precision medicine, and growing investments in genomic research are key factors fueling market expansion. The role of mRNA sequencing in disease diagnostics, drug discovery, and vaccine development is further accelerating its adoption.
Market analysis
mRNA sequencing is becoming increasingly popular because of its burgeoning contributions to drug development pipelines, disease diagnosis, and even personalized medicine. One of the most significant factors driving this market is the increasing utilization of the mRNA sequencing method in cancer studies, infectious disease research, and diagnostic tests for rare genetic disorders. The growing investment by governments and private organizations in genomics research is additionally driving the market growth. For example, in 2023, the U.S. National Institutes of Health (NIH) provided USD 5.3 billion for genomics research to promote mRNA sequencing in health advancement.
Get a Sample Report of mRNA Sequencing Market@ https://www.snsinsider.com/sample-request/4550
Major Players Analysis Listed in this Report are:
- Solvay
- Kureha Corporation
- Toray Industries, Inc.
- Mitsubishi Chemical Holdings
- SGL Group
- Royal DSM
- Formosa Plastics Corporation
- Hexcel Corporation
- Evonik Industries
- Teijin Limited
- SABIC
- Takara Bio Inc.
- Illumina, Inc.
- QIAGEN
- F. Hoffmann-La Roche Ltd
- Quantabio
- Zymo Research Corporation
- base click GmbH
- Paragon Genomics, Inc.
- Yeasen Biotechnology (Shanghai) Co., Ltd.
- Novogene Co, Ltd
- Norgen Biotek Corp and other players
mRNA Sequencing Market Report Scope
| Report Attributes | Details |
| Market Size in 2023 | US$ 3.6 billion |
| Market Size by 2032 | US$ 7.19 billion |
| CAGR | CAGR of 8.0% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Key Regional Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
Segment Analysis
By Technology
In 2023, Sequencing by synthesis(SBS) technology held the major revenue share of 34.3% in the mRNA sequencing market. SBS is preferred due to its high accuracy, expansibility, and capacity to produce large volumes of data in a short amount of time. The segments include research institutions, companies in the pharmaceuticals sector, and diagnostic labs, among others, for multiplexing gene expression analysis, variant detection, transcriptome profiling, and more. The emergence of new high-throughput NGS technologies like Illumina’s NovaSeq and Thermo Fisher’s Ion Torrent has further increased its pace of acceptance. The same is due to the declining costs of sequencing in addition to sophisticated bioinformatics tools that are now available. This makes SBS technology especially useful in cancer research, infectious disease studies, and rare genetic disorder diagnostics, and makes it a cornerstone of modern genomics research.
By Application
The largest application segment was expression profiling analysis, which accounted for a 30.1% share in 2023. This application is important to identify gene expression patterns in disease states such as cancer, cardiovascular disease, and neurological disease. mRNA sequencing is beneficial for biomarker identification, disease mechanisms study, and targeting therapy development. Its adoption has been largely fuelled by the growth of precision medicine and personalised treatment options. However, recent breakthroughs in single-cell RNA sequencing (scRNA-seq) have opened new opportunities for cellular exploration and allowed an even greater depth of biological insight by enabling the study of cellular heterogeneity and both the identification and characterization of rare cell populations. Expression profiling is a critical tool to accelerate healthcare and patient outcomes that is also used extensively for drug discovery and clinical research.
By End-User
Academic & research institutions were the largest end-user segment, accounting for 52.1% of the total mRNA sequencing market revenue in 2023. These institutions have been at the forefront of genomics research, particularly utilizing mRNA sequencing for basic research, drug discovery, and clinical studies. Key drivers have included government funding, collaborations with pharmaceutical companies, and the establishment of genomics research centers. The European Union Horizon Europe is providing a considerable amount of funding to genomics studies and allowing academic institutions to acquire the latest sequencing technologies. There is also a growing focus on understanding complex diseases and developing personalized therapies, currently, the segment is witnessing increased demand for mRNA sequencing.
Need Any Customization Research on mRNA Sequencing Market, Enquire Now@ https://www.snsinsider.com/enquiry/4550
mRNA Sequencing Market Segmentation
By Product & Service:
- Sample Preparation
- Application
- Method
- Sequencing Platforms & Consumables for RNA Sequencing
- RNA Sequencing Services
- Data Analysis, Storage, and Management
By Technology:
- Sequencing by Synthesis (SBS)
- Ion Semiconductor Sequencing
- Single-molecule Real-time (SMRT) Sequencing
- Nanopore Sequencing
By Application:
- De Novo Transcriptome Assembly
- Expression Profiling Analysis
- Variant Calling & Transcriptome Epigenetics
- Small RNA Sequencing
By End User:
- Research Centers and Academic & Government Institutes
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Companies
- Others
Regional Analysis
In 2023, North America became the leading market for mRNA sequencing, with a 42.2% share of the global revenue. The market growth in the region can be attributed to the presence of high healthcare expenditure, well-established research infrastructure, and strong government support for genomics research. In the U.S., the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) have made considerable investments in genomics and precision medicine efforts. Moreover, the region is fortified with the presence of the dominant market players, including Illumina, Thermo Fisher Scientific, and Pacific Biosciences. Moreover, the rising prevalence of chronic disease and increasing adoption of personalized medicine in North America is bolstering the mRNA sequencing market. Europe accounted for the significant share, primarily due to strict regulatory policies, high{em} end healthcare infrastructure and growing investments in genomics research. Countries such as Germany, the UK and France are at the forefront with taxpayer-funded initiatives and partnerships between universities and pharma.
The Asia-Pacific mRNA Sequencing Market is anticipated to grow at a considerable rate throughout the forecast period. The notable growth is due to significant advancements in healthcare infrastructure, soaring government funding associated with genomics research, and the growing prevalence of chronic diseases. Countries such as China, India, and Japan are pouring money into genomics and precision medicine initiatives. For example, the Chinese government’s 14th Five-Year Plan prioritizes investments in biotechnology and genomics research. Furthermore, the large patient population and rising adoption of advanced sequencing technology are also fueling growth in the region.
Recent Developments
- Thermo Fisher Scientific gained FDA approval in January 2024 for its Ion Torrent Genexus System, which combines mRNA sequencing with automated sample prep and data analysis.
Buy a Single-User PDF of mRNA Sequencing Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/4550
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
6. Competitive Landscape
7. mRNA Sequencing Market by Product & Service
8. mRNA Sequencing Market by Technology
9. mRNA Sequencing Market by Application
10. mRNA Sequencing Market by End User
11. Regional Analysis
12. Company Profiles
13. Use Cases and Best Practices
14. Conclusion
Access Complete Report Details of mRNA Sequencing Market Analysis & Outlook 2024-2032@ https://www.snsinsider.com/reports/mrna-sequencing-market-4550
[For more information or need any customization research mail us at [email protected]]
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaChron.com takes no editorial responsibility for the same.